• 한국발생생물학회지:발생과생식
• /
• 제21권3호
• /
• pp.343-349
• /
• 2017

tWith the development of the third-generation gene scissors, CRISPR-Cas9, concerns are being raised about ethical and social repercussions of the new gene-editing technology. In this situation, this article explores the legislation and interpretation of the positive laws in South Korea. The BioAct does not specify and regulate 'gene editing' itself. However, assuming that genetic editing is used in the process of research and treatment, we can look to the specific details of the regulations for research on humans as well as gene therapy research in order to see how genetic editing is regulated under the BioAct. BioAct differentiates the regulation between (born) humans and embryos etc. and the regulation differ entirely in the manner and scope. Moreover, due to the fact that gene therapy products are regarded as drugs, they fall under different regulations. The Korean Pharmacopoeia Act put stringent sanctions on clinical trials for gene therapy products and the official Notification "Approval and Examination Regulations for Biological Products, etc." by Food and Drug Safety Administration may be applied to gene editing for gene therapy purposes.

• Animal Bioscience
• /
• 제35권6호
• /
• pp.791-803
• /
• 2022

Genome/gene-editing (GE) techniques, characterized by a low technological barrier, high efficiency, and broad application among organisms, are now being employed not only in medical science but also in agriculture/veterinary science. Different engineered CRISPR/Cas9s have been identified to expand the application of this technology. In pig production, GE is a precise new breeding technology (NBT), and promising outcomes in improving economic traits, such as growth, lean or healthy meat production, animal welfare, and disease resistance, have already been documented and reviewed. These promising achievements in porcine gene editing, including the Myostatin gene knockout (KO) in indigenous breeds to improve lean meat production, the uncoupling protein 1 (UCP1) gene knock-in to enhance piglet thermogenesis and survival under cold stress, the generation of GGTA1 and CMP-N-glycolylneuraminic acid hydroxylase (CMAH) gene double KO (dKO) pigs to produce healthy red meat, and the KO or deletion of exon 7 of the CD163 gene to confer resistance to porcine reproductive and respiratory syndrome virus infection, are described in the present article. Other related approaches for such purposes are also discussed. The current trend of global regulations or legislation for GE organisms is that they are exempted from classification as genetically modified organisms (GMOs) if no exogenes are integrated into the genome, according to product-based and not process-based methods. Moreover, an updated case study in the EU showed that current GMO legislation is not fit for purpose in term of NBTs, which contribute to the objectives of the EU's Green Deal and biodiversity strategies and even meet the United Nations' sustainable development goals for a more resilient and sustainable agri-food system. The GE pigs generated via NBT will be exempted from classification as GMOs, and their global valorization and commercialization can be foreseen.

• Journal of Plant Biotechnology
• /
• 제46권3호
• /
• pp.137-142
• /
• 2019

유전자교정작물은 공여 DNA의 사용 여부와 돌연변이의 크기에 따라 SDN-1, SDN-2, SDN-3 작물로 분류한다. 특히 SDN-1과 SDN-2 작물들은 이들을 창출하기 위하여 사용한 운반체 DNA 단편 또는 guide RNA가 잔존 하지 않는 100% transgene-free 작물의 개발이 가능하다. 따라서 이들은 기존의 전통교배육종기술을 이용하거나 자연 상태에서도 창출이 가능한 작물들이다. 그러므로 기존의 GMO 법령에 따라 이들 유전자교정작물을 판별하거나 표시제에 근거한 관리 감독을 수행하기가 어렵다. 이러한 과학적 사실에 근거하여 호주는 SDN-1 작물은 GMO 규제에서 제외하도록 하였다. 또한, 아르헨티나, 브라질, 일본 등은 외래유전자가 최종산물에 잔존 하지 않는 유전자교정작물은 GMO 규제에서 제외하도록 하여 SDN-1은 물론 SDN-2 작물도 GMO에 포함되지 않을 수도 있도록 하였다. 이러한 추세에 따라 우리나라도 외래유전자가 잔존 하지 않는 유전자교정작물은 GMO 규제에서 제외하도록 하여 유전자교정기술을 이용한 다양한 작물 육종 계통 육성이 널리 이용되어 우수 품종 육성에 기여되길 기대한다.